688553 汇宇制药
2025/09 - 九个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入741,750-12.92%1,094,382927,0751,493,2681,823,733
减:营业总成本685,551-7.54%1,006,585873,7121,304,3121,382,450
    其中:营业成本144,7120.83%181,511130,447176,182157,299
               财务费用(32,548)137.66%(22,120)(41,802)(46,899)(4,955)
               资产减值损失(1,468)-84.72%(14,814)(2,307)(3,933)(2,892)
公允价值变动收益(160,999)-239.39%239,8566,4402,3276,156
投资收益3,332-78.32%13,81534,18342,89412,845
    其中:对联营企业和合营企业的投资收益326-49.68%(2,687)3071,4711,016
营业利润(77,309)-131.63%348,432124,368235,448478,755
利润总额(76,285)-130.51%349,699132,154238,391477,700
减:所得税费用(21,215)-172.44%33,802(7,180)(10,599)31,841
净利润(55,070)-124.94%315,897139,335248,991445,859
减:非控股权益(4,265)-35.25%(9,493)(451)----
股东净利润(50,805)-122.35%325,390139,786248,991445,859

市场价值指针
每股收益 (元) *-0.120-122.22%0.7700.3300.5901.200
每股派息 (元) *----0.4630.2130.2350.211
每股净资产 (元) *8.808-3.84%9.3938.9018.7778.400
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容